Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 101-PGC-005 in Moderate to Severe COVID-19
NCT05195749Phase 2Terminated
- Sponsor
- 101 Therapeutics
- Start
- Jan 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 101-PGC-005 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by 101 Therapeutics. Primary endpoints: Safety of '005 in moderate to severe COVID-19 patients with Standard of Care treatment at day 2, Safety of '005 in moderate to severe COVID-19 patients with Standard of Care treatment at day 3 and 2 more. Started Jan 2022; status: terminated.
02
Drugs
101-PGC-005
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05195749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195749.